Coronavirus (COVID-19) News
Filter News
Found 2,241 articles
-
Kroger Health Reduces Barriers to COVID-19 Treatment Options Nationwide
4/29/2022
Kroger Health, the healthcare division of The Kroger Co. Family of Companies, urges Americans to remain diligent in seeking proper testing and care for COVID-19.
-
Moderna has made the official request to the FDA to approve its COVID-19 for use in children ages 6 months to 5 years. Moderna also announced the location of its first non-U.S. mRNA manufacturing facility.
-
AB Science announced the continuation of the Phase 2 study evaluating masitinib in combination with isoquercetin in COVID-19, following the recommendation of the Data and Safety Monitoring Board (DSMB)
4/28/2022
AB Science SA announced the continuation of the Phase 2 study evaluating masitinib in combination with isoquercetin in COVID-19, following the recommendation of the Data and Safety Monitoring Board.
-
GlaxoSmithKline exceeded expectations for its first-quarter sales and earnings forecasts. This was largely driven by its sales of Xevudy, an antibody treatment against COVID-19 it developed with Vir Biotechnology, and its Shingrix vaccine against shingles.
-
The U.S. Congress is calling for the coronavirus management plan to deliberate on the timeline for the approval and release of vaccines for children under 5 years old.
-
How many boosters are enough to protect against COVID-19 infection? This question has been at the forefront of the minds of everyone as news crops up about yearly boosters.
-
The FDA has now approved the first treatment for COVID-19 in young children, expanding its approval for Gilead's Veklury to children who are at least 28 days old and weigh at least three kilograms.
-
With COVID-19 still very much a threat to the public, researchers are working on developing new treatments. Read on for more updates.
-
The DSMB for Ocugen's Phase I/II trial of OCU400, a gene therapy in development for Retinitis Pigmentosa (RP), recommended the study proceed with enrolling more patients.
-
It was yet another busy week for clinical trial news, with a range of studies for COVID-19, various cancers, fungal infections and other indications.
-
Mawi iSWAB Microbiome-EL Enables Prime Discoveries’ Development of Rapid Extraction-Less COVID Diagnostic Assay
4/25/2022
Mawi DNA Technologies, a biotechnology company focusing on the development of innovative technologies for biosampling, announces that Prime Discoveries has successfully developed CovidDetect™, a rapid isothermal amplification diagnostic assay for detecting SARS-CoV-2.
-
New Data for Shionogi’s COVID-19 Once-Daily Oral Antiviral S-217622 Show Rapid Virus Clearance
4/23/2022
Shionogi & Co., Ltd. announced new results from two late-breaking presentations of S-217622 at the 32nd European Congress of Clinical Microbiology & Infectious Diseases in Lisbon, 23 – 26 April.
-
As Omicron dominates the COVID-19 landscape, scientists are urging the FDA to reconsider how the agency defines immune responses.
-
The WHO has indicated support for Pfizer’s Paxlovid and reversing a previous decision on using antiviral remdesivir, now recommending it in cases of mild to moderate COVID-19.
-
Long COVID is loosely defined as COVID-19 symptoms that persist for longer than four weeks from an initial diagnosis. Here’s a look at the latest in long COVID research.
-
Research Roundup: COVID-19 Pneumonia and Dementia Risk, Prostate Cancer Advances - and Oreos
4/22/2022
COVID-19 continues to generate surprises, such as a possible link between dementia and severe COVID-19. Continue reading for that and more research stories. -
Moderna is poised to seek the regulatory authorization of its COVID-19 vaccine in children between six months and 5 years.
-
The FDA noted that the EUA application for Novavax's COVID-19 shot may take a while to be resolved, citing an "incredibly complex review process."
-
Clinical results announced this week could expand COVID-19 prevention options for the immunocompromised and vaccine ineligible, as well as those that have already contracted COVID.
-
SpeeDx Expand COVID-19 Diagnostics to Include Self-Collected Samples
4/21/2022
SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, have added saliva to the list of validated samples for their PlexPCR® SARS-CoV-2 qPCR diagnostic for COVID-19 sales across Europe#.